Drug intelligence / Profile preview

ENB110

Development stage: Preclinical
Lead developer: EnnovaBio
Modality: Small Molecules

Overview

ENB110 is a small molecule inhibitor currently in preclinical development by EnnovaBio Pharmaceuticals. It is designed to target the Receptor Activator of Nuclear Factor-kappa B (RANK) pathway, which plays a pivotal role in the regulation of immune responses and the differentiation of osteoclasts. By modulating RANK-related signaling, ENB110 aims to treat various autoimmune and inflammatory diseases. The drug was identified through EnnovaBio's informatics-guided discovery platform, which focuses on novel inhibitors for key nodes in immune regulation.

Targets

TNFRSF11A (RANK)

Beyond the preview

Go deeper on ENB110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENB110.

Explore the full profile